Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. 2023

So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

OBJECTIVE The benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. This study aimed to assess the survival benefit of adjuvant chemotherapy in this patient population. This retrospective study included 218 patients with localized non-metastatic PDAC who received neoadjuvant FOLFIRINOX and underwent curative-intent surgery (R0 or R1) between January 2017 and December 2020. The association of adjuvant chemotherapy with disease-free survival (DFS) and overall survival (OS) was evaluated in overall patients and in the propensity score matched (PSM) cohort. Subgroup analysis was conducted according to the pathology-proven lymph node status. RESULTS Adjuvant chemotherapy was administered to 149 patients (68.3%). In the overall cohort, the adjuvant chemotherapy group had significantly improved DFS and OS compared to the observation group (DFS: median, 13.8 months [95% confidence interval (CI), 11.0 to 19.1] vs. 8.2 months [95% CI, 6.5 to 12.0]; p < 0.001; and OS: median, 38.0 months [95% CI, 32.2 to not assessable] vs. 25.7 months [95% CI, 18.3 to not assessable]; p=0.005). In the PSM cohort of 57 matched pairs of patients, DFS and OS were better in the adjuvant chemotherapy group than in the observation group (p < 0.001 and p=0.038, respectively). In the multivariate analysis, adjuvant chemotherapy was a significant favorable prognostic factor (vs. observation; DFS: hazard ratio [HR], 0.51 [95% CI, 0.36 to 0.71; p < 0.001]; OS: HR, 0.45 [95% CI, 0.29 to 0.71; p < 0.001]). CONCLUSIONS Among PDAC patients who underwent surgery following neoadjuvant FOLFIRINOX, adjuvant chemotherapy may be associated with improved survival. Randomized studies should be conducted to validate this finding.

UI MeSH Term Description Entries
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy
D020360 Neoadjuvant Therapy Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy. Neoadjuvant Chemoradiation,Neoadjuvant Chemoradiation Therapy,Neoadjuvant Chemoradiation Treatment,Neoadjuvant Chemoradiotherapy,Neoadjuvant Chemotherapy,Neoadjuvant Chemotherapy Treatment,Neoadjuvant Radiation,Neoadjuvant Radiation Therapy,Neoadjuvant Radiation Treatment,Neoadjuvant Radiotherapy,Neoadjuvant Systemic Therapy,Neoadjuvant Systemic Treatment,Neoadjuvant Treatment,Chemoradiation Therapy, Neoadjuvant,Chemoradiation Treatment, Neoadjuvant,Chemoradiation, Neoadjuvant,Chemoradiotherapy, Neoadjuvant,Chemotherapy Treatment, Neoadjuvant,Chemotherapy, Neoadjuvant,Neoadjuvant Chemoradiation Therapies,Neoadjuvant Chemoradiation Treatments,Neoadjuvant Chemoradiations,Neoadjuvant Chemoradiotherapies,Neoadjuvant Chemotherapies,Neoadjuvant Chemotherapy Treatments,Neoadjuvant Radiation Therapies,Neoadjuvant Radiation Treatments,Neoadjuvant Radiations,Neoadjuvant Radiotherapies,Neoadjuvant Systemic Therapies,Neoadjuvant Systemic Treatments,Neoadjuvant Therapies,Neoadjuvant Treatments,Radiation Therapy, Neoadjuvant,Radiation Treatment, Neoadjuvant,Radiation, Neoadjuvant,Radiotherapy, Neoadjuvant,Systemic Therapy, Neoadjuvant,Systemic Treatment, Neoadjuvant,Therapy, Neoadjuvant,Therapy, Neoadjuvant Chemoradiation,Therapy, Neoadjuvant Radiation,Therapy, Neoadjuvant Systemic,Treatment, Neoadjuvant,Treatment, Neoadjuvant Chemoradiation,Treatment, Neoadjuvant Chemotherapy,Treatment, Neoadjuvant Radiation,Treatment, Neoadjuvant Systemic
D021441 Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS. Pancreatic Ductal Carcinoma,Carcinoma, Ductal, Pancreatic,Duct-Cell Carcinoma of the Pancreas,Duct-Cell Carcinoma, Pancreas,Ductal Carcinoma of the Pancreas,Pancreatic Duct Cell Carcinoma,Carcinoma, Pancreas Duct-Cell,Carcinomas, Pancreas Duct-Cell,Carcinomas, Pancreatic Ductal,Duct Cell Carcinoma of the Pancreas,Duct Cell Carcinoma, Pancreas,Duct-Cell Carcinomas, Pancreas,Ductal Carcinoma, Pancreatic,Ductal Carcinomas, Pancreatic,Pancreas Duct-Cell Carcinoma,Pancreas Duct-Cell Carcinomas,Pancreatic Ductal Carcinomas

Related Publications

So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
June 2021, European radiology,
So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
October 2021, Annals of surgical oncology,
So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
October 2023, International journal of surgery (London, England),
So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
July 2020, Histopathology,
So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
December 2019, Oncotarget,
So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
September 2022, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
August 2020, American journal of clinical oncology,
So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
March 2024, International journal of surgery (London, England),
So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
March 2018, JOP : Journal of the pancreas,
So Heun Lee, and Dae Wook Hwang, and Changhoon Yoo, and Kyu-Pyo Kim, and Sora Kang, and Jae Ho Jeong, and Dongwook Oh, and Tae Jun Song, and Sang Soo Lee, and Do Hyun Park, and Dong Wan Seo, and Jin-Hong Park, and Ki Byung Song, and Jae Hoon Lee, and Woohyung Lee, and Yejong Park, and Bong Jun Kwak, and Heung-Moon Chang, and Baek-Yeol Ryoo, and Song Cheol Kim
May 2024, Annals of hepato-biliary-pancreatic surgery,
Copied contents to your clipboard!